Vincent Medical AGM: Shareholders Clear All Resolutions, Sanction HK2.60-Cent Final Dividend and Fresh Mandates

Bulletin Express
05/20

Vincent Medical Holdings Limited announced that shareholders approved every item on the agenda at the 20 May 2026 Annual General Meeting (AGM). Voting was conducted by poll, with Tricor Investor Services acting as scrutineer.

Key outcomes:

1. Financial Statements and Dividend • The audited consolidated results for the year ended 31 December 2025 were adopted with 99.66 % support (421.70 million votes in favour versus 1.44 million against). • A final cash dividend of HK 2.60 cents per share for FY2025 secured unanimous approval (100 % support on 423.14 million votes).

2. Board and Auditor Re-appointments • Executive Director Mr Choi Man Shing, Non-executive Director Dr Leung Ming Chu, and Independent Non-executive Director Mr Mok Kwok Cheung Rupert were each re-elected with support levels between 99.74 % and 99.80 %. • Directors’ remuneration will continue to be set by the Board following a 100 % affirmative vote. • RSM Hong Kong was re-appointed as auditor, also with unanimous backing.

3. Capital Management Mandates • A general mandate allowing the Board to issue new shares up to 20 % of issued share capital passed with 94.66 % approval (400.52 million votes for; 22.62 million against). • Authority to repurchase up to 10 % of shares gained full support, and the extension of the issue mandate by the amount of repurchased shares was likewise approved by 94.66 % of votes.

4. Corporate Governance Update • Shareholders endorsed a new Memorandum and Articles of Association, with 100 % of votes in favour—surpassing the 75 % threshold required for special resolutions.

Participation and Governance • The company had 659.58 million shares in issue on the record date, all eligible to vote. • Maximum votes cast on any resolution reached 423.14 million, indicating a participation rate of approximately 64 %. • All directors attended the AGM in person.

The approvals provide Vincent Medical with flexibility for future capital actions while confirming shareholder support for its current leadership and FY2025 financial performance.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10